Accelerate Diagnostics Inc.
08/15/2022 | Press release | Distributed by Public on 08/15/2022 05:23
BD and Accelerate Diagnostics Announce Global Commercial Collaboration
BD and Accelerate Diagnostics Announce Global Commercial Collaboration
Aug 15, 2022
Today we announced a global commercial collaboration agreement with BD (Becton, Dickinson and Company) to market and sell the Accelerate Pheno® system and Accelerate Arc™ module and associated test kits throughout its global network. These solutions complement BD's existing product portfolio to advance our shared mission to address the global threat of antimicrobial resistance and improve the lives of patients with serious infections.
As one of the largest global medical technology companies in the world, BD has the ability to commercialize worldwide. This provides a unique opportunity to address antimicrobial resistance on a global scale. AMR knows no boundaries. The partnership with Accelerate Diagnostics offers the best chance of bringing innovative technologies to any hospital to target these superbugs.
What does this mean for Accelerate customers?
From a patient care perspective, this new collaboration expands the possibility of more timely results to inform optimal therapeutic solutions.
In today's marketplace, it is critical to have the scale and influence to maintain a sustained presence in the clinical environment. This is noteworthy coming out of the COVID-19 pandemic. Today's laboratories are looking to partner with larger multi-national corporations that can stand the test of time and offer expanded product portfolios which address present and future needs.
Customers will continue to order products and receive customer and technical support directly from Accelerate Diagnostics.
Why did Accelerate Diagnostics decide to partner with BD?
Accelerate Diagnostics has singularly defined the rapid positive blood culture ID/AST market and has made strong inroads into the adoption of its innovative systems in the US and EMEA geographies. Given the recent healthcare landscape changes, especially coming out of the COVID-19 pandemic in which laboratorians have limited time and availability to meet with numerous vendors, having a singular commercial team, represented by an industry leader is advantageous both in terms of account access as well as representing an entire suite of microbiologic solutions.
BD's global footprint provides the access and the account intimacy that is expected to foster more sales opportunities around the world, including over time in countries where Accelerate Diagnostics does not yet have a commercial presence and upon receiving appropriate regulatory clearances and registrations.
Why did BD decide to partner with Accelerate Diagnostics?
BD is committed to help slow the spread of antimicrobial resistance. Not only are rapid diagnostics an important part of this solution, but the market is asking for ways to process time-sensitive samples faster, with less resources. Further, BD sees Accelerate Diagnostics' solutions as an important part of addressing this market need, and in turn improving patient outcomes, preserving antibiotic usage, and reducing overall healthcare expenditures.
Accelerate has shown that with its Pheno system, patients with acute infections, notably, bacteremia, can receive targeted antibiotic therapy days sooner than current standard of care laboratory methods. This improves both patient morbidity and healthcare economics. Further, Accelerate's suite of diagnostic systems, including Pheno and Arc, are complementary to BD's suite of clinical microbiology systems and fit very nicely into the BD sales process which is focused on providing customers with solutions across the full clinical microbiology workflow.
Read the announcement at bd.com >
How does this impact Accelerate Diagnostics?
This collaboration gives Accelerate Diagnostics additional opportunities for growth in the clinical microbiology ID/AST space, while creating the opportunity to increase market penetration. The anticipated increase in revenue will lead to a healthier company and additional growth and benefits for our employees.
What does the Accelerate Pheno® system do?
The Accelerate Pheno system uses consumable Accelerate PhenoTest™ BC kits to provide rapid antimicrobial susceptibility results, with optional organism identification direct from positive blood cultures. The Accelerate PhenoTest® BC kit is the only test approved by the U.S. Food and Drug Administration that can deliver both rapid identification and phenotypic antimicrobial susceptibility results in hours direct from positive blood cultures. These results are available to report to clinicians an average of 40 hours earlier than current traditional laboratory methods. This enables clinicians to optimize antimicrobial therapy specific to their patient's infection days earlier. It is well established in peer-reviewed literature that improving time to optimal therapy benefits both patient outcomes and hospital operations.
What does the Accelerate Arc™ module do?
The Accelerate Arc module is a simple load-and-go system that reduces the need for lengthy hands-on time by automating the workflow for direct MALDI ID. It is currently US-IVD, CE-IVDR and UKAC registered for positive blood cultures.
"Accelerate Diagnostics" and diamond shaped logos and marks are registered trademarks of Accelerate Diagnostics, Inc. Any trade, product or service name referenced in this document using the name "Accelerate" is a trademark and/or property of Accelerate Diagnostics, Inc. All other company and product names may be trademarks, registered trademarks, or service marks of the companies with which they are associated.